The US Preventive Services Task Force recommends against initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) in adults 60 years or older. The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one. Evidence indicates that the net benefit of aspirin use in this group is small. Persons who are not at increased risk for bleeding and are willing to take low-dose aspirin daily are more likely to benefit. This recommendation replaces the 2016 recommendation. The update is based on a systematic review on the effect of aspirin use on CVD and colorectal cancer and a microsimulation modeling study to assess the net balance of benefits and harms. Both CVD and bleeding risk increase with age. The benefits of initiating aspirin use are greater with higher CVD risk but become smaller with aging. Source: https://jamanetwork.com/
Higher nighttime light exposure was associated with adverse changes in cardiac structure and function and…
In two UK cohorts including 977,282 adults, drinking beverages at a “very hot” temperature was…
In a UK prospective cohort of 502,188 adults followed for a median of 13.6 years,…
Regular smoking was associated with a lower risk of Parkinson disease (PD), and among people…
Alcohol-attributable cancer deaths in the USA doubled from 11,361 in 1990 to 23,126 in 2023,…
A systematic review and meta-analysis found that the prevalence of unruptured intracranial aneurysms (UIAs) is…
This website uses cookies.